Abstract
Papillomaviruses are viruses with double-stranded DNA that are epitheliotropic and non-enveloped that infects cutaneous epithelial and mucosal cells in a species-specific way in several higher vertebrate species and cause cellular growth."There are around 100 different human papillomaviruses (HPVs)", as "more than 150 HPV types have been isolated and fully sequenced". We classify the probability of cancer development following viral infection with each HPV genotype into two types: “low-risk” and “high-risk.” As a result, HPV diagnosis is a critical component of HPV genotype identification and characterization. Based on its activities, we may classify the HPV genome into three regions: the long control region (LCR) or the non-coding upstream regulatory region (URR), the late (L) region, and the early (E) region. Functional proteins are mostly static things that are not inflexible; they have undergone both local and global movements at various times and time ranges. The structural differences between HPV16 and 18 discovered by molecular modeling of the E6 oncoprotein were associated with their carcinogenic characteristics. Similarly, the E6 protein has two sets of C-X-X-C motifs that play significant roles in transformation, transcriptional activation, interactions, and immortalization with other proteins of cells in the host environment. Here, we review the literature regarding the protein mechanisms associated with HPV and how they cause cancer. Unless otherwise noted, it described all protein activities in terms of HPV proteins. The term “papillomaviruses” refers to groups of papillomavirus proteins that have a characteristic in common. HPV proteins can study the genetic influences on pathogenicity and the therapeutic applications of genomics. The future study provides a potential advancement in HPV infections and malignant illnesses to improve preventive and treatment strategies. Patients have been able to conquer this condition using a range of therapies and vaccines that were projected to be effective and robust enough to put an end to the ailment completely. In cancer prevention strategies, HPV vaccination is one of the most effective. It is safe, efficient, and long-lasting.
Similar content being viewed by others
Data availability and materials
Not applicable.
Code availability
Not applicable.
Abbreviations
- HPV:
-
Human Papilloma virus
- URR:
-
Upstream regulatory region
- LCR:
-
Long control region
- HSV:
-
Human Sarcoma virus
- HIV:
-
Human immuno virus
- WHO:
-
World health organization
- ICC:
-
Invasive cervical cancer
- LSIC:
-
Low grade squamous intraepithelial lesions
- HSIC:
-
High grade squamous intraepithelial lesions
- ASCUS:
-
Atypical squamous cells of undetermined significance
- ORF:
-
Open reading frames
References
Aksoy P, Gottschalk EY, Meneses PI. HPV entry into cells. Mutat Res Rev Mutat Res. 2017. https://doi.org/10.1016/j.mrrev.2016.09.004.
Apt D, Watts RM, Suske G, Bernard HU. High Sp1/Sp3 ratios in epithelial cells during epithelial differentiation and cellular transformation correlate with the activation of the HPV-16 promoter. Virology. 1996. https://doi.org/10.1006/viro.1996.0530.
Bansal A, Singh MP, Rai B. Human papillomavirus-associated cancers: a growing global problem. Int J Appl Basic Med Res. 2016. https://doi.org/10.4103/2229-516X.179027.
Bassi C, Li YT, Khu K, Mateo F, Baniasadi PS, Elia A, Mason J, Stambolic V, Pujana MA, Mak TW, Gorrini C. The acetyltransferase Tip60 contributes to mammary tumorigenesis by modulating DNA repair. Cell Death Differ. 2016. https://doi.org/10.1038/cdd.2015.173.
Bergvall M, Melendy T, Archambault J. The E1 proteins. Virology. 2013. https://doi.org/10.1016/j.virol.2013.07.020.
Bergvall M, Melendy T, Archambault J. The E1 proteins. Virology. 2013;445(1–2):35–56.
Brimer N, Lyons C, Vande Pol SB. Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein. Virology. 2007. https://doi.org/10.1016/j.virol.2006.08.038.
Bronnimann MP, Calton CM, Chiquette SF, Li S, Lu M, Chapman JA, Bratton KN, Schlegel AM, Campos SK. Furin cleavage of L2 during papillomavirus infection: minimal dependence on cyclophilins. J Virol. 2016. https://doi.org/10.1128/JVI.00038-16.
Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, Brotons M, Mena M, Cosano R, Muñoz J. Human papillomavirus and related diseases in Kenya. Summary report. 2016.
Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003. https://doi.org/10.1128/CMR.16.1.1-17.2003.
Castro-Muñoz LJ, Manzo-Merino J, Muñoz-Bello JO, Olmedo-Nieva L, Cedro-Tanda A, Alfaro-Ruiz LA, Hidalgo-Miranda A, Madrid-Marina V, Lizano M. The Human Papillomavirus (HPV) E1 protein regulates the expression of cellular genes involved in immune response. Sci Rep. 2019. https://doi.org/10.1038/s41598-019-49886-4.
Celegato M, Messa L, Bertagnin C, Mercorelli B, Loregian A. Targeted disruption of E6/p53 binding exerts broad activity and synergism with paclitaxel and topotecan against HPV-transformed cancer cells. Cancers. 2022;14(1):193.
Celewicz A, Celewicz M, Michalczyk M, Rzepka R. Perspectives in HPV secondary screening and personalized therapy basing on our understanding of HPV-related carcinogenesis pathways. Mediators Inflamm. 2020. https://doi.org/10.1155/2020/2607594.
Cerqueira C, SamperioVentayol P, Vogeley C, Schelhaas M. Kallikrein-8 proteolytically processes human papillomaviruses in the extracellular space to facilitate entry into host cells. J Virol. 2015. https://doi.org/10.1128/JVI.00234-15.
DiGiuseppe S, Bienkowska-Haba M, Guion LGM, Keiffer TR, Sapp M. Human papillomavirus major capsid protein L1 remains associated with the incoming viral genome throughout the entry process. J Virol. 2017. https://doi.org/10.1128/JVI.00537-17.
DiMaio D, Mattoon D. Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene. 2001. https://doi.org/10.1038/sj.onc.1204915.
DiMaio D, Petti LM. The E5 proteins. Virology. 2013. https://doi.org/10.1016/j.virol.2013.05.006.
DiMaio D, Petti LM. The E5 proteins. Virology. 2013;445(1–2):99–114.
Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006. https://doi.org/10.1042/CS20050369.
Doorbar J. The E4 protein; structure, function and patterns of expression. Virology. 2013. https://doi.org/10.1016/j.virol.2013.07.008.
Đukić A, Lulić L, Thomas M, Skelin J, Bennett Saidu NE, Grce M, Banks L, Tomaić V. HPV oncoproteins and the ubiquitin proteasome system: a signature of malignancy? Pathogens. 2020. https://doi.org/10.3390/pathogens9020133.
D’Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med. 2011;53(Suppl 1):S5-11.
Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital. 2014;34(5):299–309.
Favre M. Structural polypeptides of rabbit, bovine, and human papillomaviruses. J Virol. 1975. https://doi.org/10.1128/JVI.15.5.1239-1247.1975.
Freitas de AC, de Oliveira THA, Barros MR Jr, Venuti A. hrHPV E5 oncoprotein: immune evasion and related immunotherapies. J Exp Clin Cancer Res. 2017. https://doi.org/10.1186/s13046-017-0541-1.
Ganesan S, Subbiah VN, Michael JC. Associated factors with cervical pre-malignant lesions among the married fisher women community at Sadras, Tamil Nadu. Asia Pac J Oncol Nurs. 2015;2(1):42–50. https://doi.org/10.4103/2347-5625.146223.
Gao G, Smith DI. Human papillomavirus and the development of different cancers. Cytogenet Genome Res. 2016. https://doi.org/10.1159/000458166.
Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006. https://doi.org/10.1038/sj.onc.1209615.
Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(10 Suppl):3036–46.
Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002. https://doi.org/10.1152/physrev.00027.2001.
Graham SV. Human papillomavirus E2 protein: linking replication, transcription, and RNA processing. J Virol. 2016. https://doi.org/10.1128/JVI.00502-16.
Graham SV. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clin Sci (Lond). 2017. https://doi.org/10.1042/CS20160786.
Grm HS, Massimi P, Gammoh N, Banks L. Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoprotein. Oncogene. 2005;24(33):5149–64.
Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017. https://doi.org/10.1016/j.mrrev.2016.07.002.
Houlihan CF, Baisley K, Bravo IG, Pavón MA, Changalucha J, Kapiga S, De Sanjosé S, Ross DA, Hayes RJ, Watson-Jones D. Human papillomavirus DNA detected in fingertip, oral and bathroom samples from unvaccinated adolescent girls in Tanzania. Sex Transm Infect. 2019. https://doi.org/10.1136/sextrans-2018-053756.
Howley PM, Pfister HJ. Beta genus papillomaviruses and skin cancer. Virology. 2015;479–480:290–6. https://doi.org/10.1016/j.virol.2015.02.004.
Hull R, Mbele M, Makhafola T, Hicks C, Wang SM, Reis RM, Mehrotra R, Mkhize-Kwitshana Z, Kibiki G, Bates DO, Dlamini Z. Cervical cancer in low and middle-income countries. Oncol Lett. 2020. https://doi.org/10.3892/ol.2020.11754.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Huma. 2012;100:1–441.
Jayavardhini B, Kumar C, Vijayashree R, Vedakumari SW. Recent Advancements in Nanomedicine for Cancer Diagnosis. NanoBioMedicine.:63.
Jha S, Vande Pol S, Banerjee NS, Dutta AB, Chow LT, Dutta A. Destabilization of TIP60 by human papillomavirus E6 results in attenuation of TIP60-dependent transcriptional regulation and apoptotic pathway. Mol Cell. 2010. https://doi.org/10.1016/j.molcel.2010.05.020.
Kurg R. The role of E2 proteins in papillomavirus DNA replication. In: DNA replication-current advances. London: IntechOpen; 2011.
Laaneväli A, Ustav M, Ustav E, Piirsoo M. E2 protein is the major determinant of specificity at the human papillomavirus origin of replication. PLoS ONE. 2019. https://doi.org/10.1371/journal.pone.0224334.
Letian T, Tianyu Z. Cellular receptor binding and entry of human papillomavirus. Virol J. 2010. https://doi.org/10.1186/1743-422X-7-2.
Mahal BA, Catalano PJ, Haddad RI, Hanna GJ, Kass JI, Schoenfeld JD, Tishler RB, Margalit DN. Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019. https://doi.org/10.1158/1055-9965.EPI-19-0038.
Marklund L, Hammarstedt L. Impact of HPV in oropharyngeal cancer. J Oncol. 2011. https://doi.org/10.1155/2011/509036.
Martel de C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020. https://doi.org/10.1016/S2214-109X(19)30488-7.
McBride AA. The papillomavirus E2 proteins. Virology. 2013. https://doi.org/10.1016/j.virol.2013.06.006.
McLaughlin-Drubin ME, Münger K. The human papillomavirus E7 oncoprotein. Virology. 2009. https://doi.org/10.1016/j.virol.2008.10.006.
Mirabello L, Yeager M, Yu K, Clifford GM, **ao Y, Zhu B, Cullen M, Boland JF, Wentzensen N, Nelson CW, Raine-Bennett T, Chen Z, Bass S, Song L, Yang Q, Steinberg M, Burdett L, Dean M, Roberson D, Mitchell J, Lorey T, Franceschi S, Castle PE, Walker J, Zuna R, Kreimer AR, Beachler DC, Hildesheim A, Gonzalez P, Porras C, Burk RD, Schiffman M. HPV16 E7 genetic conservation is critical to carcinogenesis. Cell. 2017. https://doi.org/10.1016/j.cell.2017.08.001.
Mirghani H, Amen F, Blanchard P, Moreau F, Guigay J, Hartl DM, et al. Treatment de-escalation in HPV-positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives. Int J Cancer. 2015;136:1494–503.
Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550–60.
Mühr L, Eklund C, Dillner J. Towards quality and order in human papillomavirus research. Virology. 2018. https://doi.org/10.1016/j.virol.2018.04.003.
Müller M, Prescott EL, Wasson CW, Macdonald A. Human papillomavirus E5 oncoprotein: function and potential target for antiviral therapeutics. Futur Virol. 2015;10(1):27–39.
Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci. 2007;98(10):1505–11.
Nascimento KC. Avaliação da presença do Papilomavírushumano (HPV) no sangueperiférico de mulheres com lesõesintraepiteliais de alto grau e baixograu (Master's thesis, Universidade Federal de Pernambuco).
Nishimura A, Ono T, Ishimoto A, Dowhanick JJ, Frizzell MA, Howley PM, Sakai H. Mechanisms of human papillomavirus E2-mediated repression of viral oncogene expression and cervical cancer cell growth inhibition. J Virol. 2000. https://doi.org/10.1128/jvi.74.8.3752-3760.2000.
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4:e609–16. https://doi.org/10.1016/S2214-109X(16)30143-7.
Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014. https://doi.org/10.1016/j.oraloncology.2013.12.019.
Quint KD, Genders RE, de Koning MN, Borgogna C, Gariglio M, Bouwes Bavinck JN, Doorbar J, Feltkamp MC. Human Beta-papillomavirus infection and keratinocyte carcinomas. J Pathol. 2015;235:342–54. https://doi.org/10.1002/path.4425.
Sailer C, Offensperger F, Julier A, Kammer KM, Walker-Gray R, Gold MG, Scheffner M, Stengel F. Structural dynamics of the E6AP/UBE3A-E6-p53 enzyme-substrate complex. Nat Commun. 2018. https://doi.org/10.1038/s41467-018-06953-0.
Sakakibara N, Mitra R, McBride AA. The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. J Virol. 2011. https://doi.org/10.1128/JVI.00541-11.
Sapp M, Bienkowska-Haba M. Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J. 2009. https://doi.org/10.1111/j.1742-4658.2009.07400.x.
Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human papillomavirus-attributable cancers—United States, 2012–2016. MMWR Morb Mortal Wkly Rep. 2019. https://doi.org/10.15585/mmwr.mm6833a3.
Shoja Z, Farahmand M, Hosseini N, Jalilvand S. A meta-analysis on human papillomavirus type distribution among women with cervical neoplasia in the WHO eastern mediterranean region. Intervirology. 2019. https://doi.org/10.1159/000502824.
Sluimer J, Distel B. Regulating the human HECT E3 ligases. Cell Mol Life Sci. 2018. https://doi.org/10.1007/s00018-018-2848-2.
Stanley MA, Winder DM, Sterling JC, Goon PK. HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: Current issues. BMC Cancer. 2012;12:398.
Subbaiah VK, Zhang Y, Rajagopalan D, Abdullah LN, Yeo-Teh NS, Tomaić V, Banks L, Myers MP, Chow EK, Jha S. E3 ligase EDD1/UBR5 is utilized by the HPV E6 oncogene to destabilize tumor suppressor TIP60. Oncogene. 2016. https://doi.org/10.1038/onc.2015.268.
Tu Y, Chen C, Pan J, Xu J, Zhou ZG, Wang CY. The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. Int J Clin Exp Pathol. 2012;5(8):726–38.
Venuti A, Paolini F, Nasir L, Corteggio A, Roperto S, Campo MS, Borzacchiello G. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer. 2011. https://doi.org/10.1186/1476-4598-10-140.
Wallace NA, Galloway DA. Novel functions of the human papillomavirus E6 oncoproteins. Annu Rev Virol. 2015. https://doi.org/10.1146/annurev-virology-100114-055021.
Wang X, Meyers C, Wang H-K, Chow LT, Zheng Z-M. Construction of a full transcription map of human papillomavirus type 18 during productive viral infection. J Virol. 2011;85(16):8080–92.
Wang JW, Roden RB. L2, the minor capsid protein of papillomavirus. Virology. 2013. https://doi.org/10.1016/j.virol.2013.04.017.
Yajid AI, Zakariah MA, Mat Zin AA, Othman NH. Potential role of E4 protein in human papillomavirus screening: a review. Asian Pac J Cancer Prev. 2017. https://doi.org/10.22034/APJCP.2017.18.2.315.
Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005. https://doi.org/10.4143/crt.2005.37.6.319.
zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002. doi: https://doi.org/10.1038/nrc798.
Acknowledgements
The authors thank the Chettinad Academy of Research Education for the constant support and encouragement.
Funding
Not applicable.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest to report.
Consent to participate
Not applicable.
Consent for publication
All authors have read and approved the manuscript.
Ethical approval
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Balaji, D., Kalarani, I.B., Mohammed, V. et al. Potential role of human papillomavirus proteins associated with the development of cancer. VirusDis. 33, 322–333 (2022). https://doi.org/10.1007/s13337-022-00786-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13337-022-00786-8